HMG-CoA reductase inhibitors in kidney transplant recipients receiving tacrolimus: Statins not associated with improved patient or graft survival

BMC Nephrology

Volumn 11, Issue 1, 2010, Pages

  Younas, Nizar ^a   Wu, Christine M ^a   Shapiro, Ron ^b   McCauley, Jerry ^a,b   Johnston, James ^a   Tan, Henkie ^b   Basu, Amit ^b   Schaefer, Heidi ^c   Smetanka, Cynthia ^b   Winkelmayer, Wolfgang C ^d   Unruh, Mark ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CYTOMEGALOVIRUS ANTIBODY; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ADULT; ALLOGRAFT; ARTICLE; BODY MASS; DIABETES MELLITUS; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; SENESCENCE; SURVIVAL; ALLOTRANSPLANTATION; DRUG COMBINATION; DRUG EFFECT; FOLLOW UP; GRAFT REJECTION; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

ADULT; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; ORGANIZATION AND ADMINISTRATION; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 77950537612     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-11-5     Document Type: Article

References (39)

1. Meta-analysis of large randomized controlled trials to evaluate the impact of statins oncardiovascular outcomes. BM Cheung IJ Lauder CP Lau CR Kumana, Br J Clin Pharmacol 2004 57 5 640 651 10.1111/j.1365-2125.2003.02060.x 15089818
2. Atorvastatin in patients with type 2 diabetes mellitus undergoinghemodialysis. C Wanner V Krane W Marz M Olschewski JF Mann G Ruf E Ritz, N Engl J Med 2005 353 3 238 248 10.1056/NEJMoa043545 16034009 (Pubitemid 41058323)
3. Effect of fluvastatin on cardiac outcomes in renal transplantrecipients: a multicentre, randomised, placebo-controlled trial. H Holdaas B Fellstrom AG Jardine I Holme G Nyberg P Fauchald C Gronhagen-Riska S Madsen HH Neumayer E Cole, et al. Lancet 2003 361 9374 2024 2031 10.1016/S0140-6736(03)13638-0 12814712
4. Long-termcardiac outcomes in renal transplant recipients receiving fluvastatin: theALERT extension study. H Holdaas B Fellstrom E Cole G Nyberg AG Olsson TR Pedersen S Madsen C Gronhagen-Riska HH Neumayer B Maes, et al. Am J Transplant 2005 5 12 2929 2936 10.1111/j.1600-6143.2005.01105.x 16303007
5. Beneficialeffect of early initiation of lipid-lowering therapy following renaltransplantation. H Holdaas B Fellstrom AG Jardine G Nyberg C Gronhagen-Riska S Madsen HH Neumayer E Cole B Maes P Ambuhl, et al. Nephrol Dial Transplant 2005 20 5 974 980 10.1093/ndt/gfh735 15784644
6. Statin use is associated with prolonged survival of renaltransplant recipients. F Wiesbauer G Heinze C Mitterbauer F Harnoncourt WH Horl R Oberbauer, J Am Soc Nephrol 2008 19 11 2211 2218 10.1681/ASN.2008010101 18650477
7. Anti-inflammatory and immunomodulatory effects of statins. LM Blanco-Colio J Tunon JL Martin-Ventura J Egido, Kidney Int 2003 63 1 12 23 10.1046/j.1523-1755.2003.00744.x 12472764
8. HMG-CoA reductase inhibitors asimmunomodulators: potential use in transplant rejection. LJ Raggatt NC Partridge, Drugs 2002 62 15 2185 2191 10.2165/00003495-200262150-00002 12381218
9. Statins in solid organ transplantation: is therean immunosuppressive effect? JA Kobashigawa, Am J Transplant 2004 4 7 1013 1018 10.1111/j.1600-6143. 2004.00475.x 15196056
10. Statins as a newlyrecognized type of immunomodulator. B Kwak F Mulhaupt S Myit F Mach, Nat Med 2000 6 12 1399 1402 10.1038/82219 11100127
11. Statins selectively inhibit leukocytefunction antigen-1 by binding to a novel regulatory integrin site. G Weitz-Schmidt K Welzenbach V Brinkmann T Kamata J Kallen C Bruns S Cottens Y Takada U Hommel, Nat Med 2001 7 6 687 692 10.1038/89058 11385505
12. Statinuse is associated with improved function and survival of lung allografts. BA Johnson AT Iacono A Zeevi KR McCurry SR Duncan, Am J Respir Crit Care Med 2003 167 9 1271 1278 10.1164/rccm.200205-410OC 12615629
13. Prevention of primary nonfunction of canine islet autografts bytreatment with pravastatin. S Arita T Nagai M Ochiai Y Sakamoto LA Shevlin CV Smith Y Mullen, Transplantation 2002 73 1 7 12 10.1097/00007890-200201150-00003 11792971
14. Simvastatin initiated early after hearttransplantation: 8-year prospective experience. K Wenke B Meiser J Thiery D Nagel W von Scheidt K Krobot G Steinbeck D Seidel B Reichart, Circulation 2003 107 1 93 97 10.1161/01.CIR.0000043241.32523.EE 12515749
15. Comparative beneficial effects of simvastatin andpravastatin on cardiac allograft rejection and survival. MR Mehra PA Uber K Vivekananthan S Solis RL Scott MH Park RV Milani CJ Lavie, J Am CollCardiol 2002 40 9 1609 1614 10.1016/S0735-1097(02)02340-9 (Pubitemid 35256143)
16. Efficacy and safety of pravastatin vs simvastatin after cardiactransplantation. A Keogh P Macdonald A Kaan C Aboyoun P Spratt J Mundy, J Heart Lung Transplant 2000 19 6 529 537 10.1016/S1053-2498(00)00077-2 10867332
17. The effects of lipid-lowering agents on acute renalallograft rejection. BL Kasiske KL Heim-Duthoy GG Singer B Watschinger MJ Germain B Bastani, Transplantation 2001 72 2 223 227 10.1097/00007890-200107270-00009 11477342
18. The effectof pravastatin on acute rejection after kidney transplantation - a pilotstudy. S Katznelson AH Wilkinson JA Kobashigawa XM Wang D Chia M Ozawa HP Zhong M Hirata AH Cohen PI Teraski, et al. Transplantation 1996 61 10 1469 1474 10.1097/00007890-199605270-00010 8633373
19. Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renalallograft rejection. K Sahu R Sharma A Gupta S Gulati D Agarwal A Kumar M Bhandari, Clin Transplant 2001 15 3 173 175 10.1034/j.1399-0012.2001.150305.x 11389707
20. Acute renal allograft rejections, a rolefor statins? H Holdaas A Jardine, Minerva Urol Nefrol 2003 55 2 111 119 12847415
21. Effects of fluvastatin on cardiac events in renal transplantpatients: ALERT (Assessment of Lescol in Renal Transplantation) study designand baseline data. H Holdaas B Fellstrom I Holme G Nyberg P Fauchald A Jardine C Gronhagen-Riska S Madsen HH Neumayer E Cole, et al. J Cardiovasc Risk 2001 8 2 63 71 10.1097/00043798-200104000-00002 11324372
22. Effect offluvastatin on acute renal allograft rejection: a randomized multicentertrial. H Holdaas AG Jardine DC Wheeler IB Brekke PJ Conlon B Fellstrom A Hammad I Holme H Isoniemi R Moore, et al. Kidney Int 2001 60 5 1990 1997 10.1046/j.1523-1755.2001.00010.x 11703619
23. Fluvastatin reduces atherogenic lipids without any effect on nativeendothelial function early after kidney transplantation. A Asberg H Holdaas AG Jardine C Edvardsen A Hartmann, ClinTransplant 2003 17 4 385 390
24. Patient survival after renal transplantation III: theeffects of statins. FG Cosio TE Pesavento RP Pelletier M Henry RM Ferguson S Kim S Lemeshow, Am J Kidney Dis 2002 40 3 638 643 10.1053/ajkd.2002.34927 12200817
25. Impact of statin treatment on 1-year functional and histologic renalallograft outcome. R Masterson T Hewitson M Leikis R Walker S Cohney G Becker, Transplantation 2005 80 3 332 338 10.1097/01.tp.0000168941.19689.cf 16082328
26. New onset dyslipidemia after renal transplantation: is there adifference between tacrolimus and cyclosporine? S Deleuze V Garrigue S Delmas G Chong I Swarcz JP Cristol G Mourad, Transplant Proc 2006 38 7 2311 2313 10.1016/j.transproceed.2006.06.125 16980075
27. Kidneytransplantation under a tolerogenic regimen of recipient pretreatment andlow-dose postoperative immunosuppression with subsequent weaning. R Shapiro ML Jordan A Basu V Scantlebury S Potdar HP Tan EA Gray PS Randhawa N Murase A Zeevi, et al. Ann Surg 2003 238 4 520 525 discussion 525-527 14530723
28. Tolerogenicimmunosuppression for organ transplantation. TE Starzl N Murase K Abu-Elmagd EA Gray R Shapiro B Eghtesad RJ Corry ML Jordan P Fontes T Gayowski, et al. Lancet 2003 361 9368 1502 1510 10.1016/S0140-6736(03)13175-3 12737859
29. Comorbid conditions in kidney transplantation:association with graft and patient survival. C Wu I Evans R Joseph R Shapiro H Tan A Basu C Smetanka A Khan J McCauley M Unruh, J Am Soc Nephrol 2005 16 11 3437 3444 10.1681/ASN. 2005040439 16176999
30. Do OSCAR winners live longerthan less successful peers? A reanalysis of the evidence. MP Sylvestre E Huszti JA Hanley, AnnIntern Med 2006 145 5 361 363 discussion 392
31. Clinical practice guidelines for managingdyslipidemias in kidney transplant patients. BL Kasiske, Am J Transplant 2005 5 6 1576 10.1111/j.1600-6143.2005.00827.x 15888073
32. Discontinuation ratesfor use of statins are high. LA Simons J Simons P McManus J Dudley, BMJ 2000 321 7268 1084 10.1136/bmj.321.7268.1084 11053202
33. Discontinuation of statin therapy following an acute myocardialinfarction: a population-based study. SS Daskalopoulou JA Delaney KB Filion JM Brophy NE Mayo S Suissa, Eur Heart J 2008 18664465
34. Effect ofpravastatin on loss of renal function in people with moderate chronic renalinsufficiency and cardiovascular disease. M Tonelli L Moye FM Sacks T Cole GC Curhan, J Am Soc Nephrol 2003 14 6 1605 1613 10.1097/01.ASN. 0000068461.45784.2F 12761262
35. Low-dosesimvastatin is a well-tolerated and efficacious cholesterol-lowering agentin ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients. M Arnadottir LO Eriksson JI Germershausen H Thysell, Nephron 1994 68 1 57 62 10.1159/000188088 7991041
36. First UnitedKingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacyand safety of simvastatin and safety of low-dose aspirin in chronic kidneydisease. C Baigent M Landray C Leaper P Altmann J Armitage A Baxter HS Cairns R Collins RN Foley V Frighi, et al. Am J Kidney Dis 2005 45 3 473 484 10.1053/j.ajkd.2004.11.015 15754269
37. Adouble-blind placebo controlled trial of simvastatin for the treatment ofdyslipidaemia in renal allograft recipients. F Lepre R Rigby C Hawley D Saltissi A Brown Z Walsh, Clin Transplant 1999 13 6 520 525 10.1034/j.1399-0012. 1999.130613.x 10617243
38. Efficacy and drug interactions of the newHMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treatedrenal transplant recipients. L Renders I Mayer-Kadner C Koch S Scharffe K Burkhardt R Veelken RE Schmieder IA Hauser, Nephrol Dial Transplant 2001 16 1 141 146 10.1093/ndt/16.1.141 11209008
39. Safety andefficacy of simvastatin for hyperlipidemia in renal transplant recipients: adouble-blind, randomized, placebo-controlled study. AF Santos E Keitel AE Bittar J Neumann FD Fuchs JC Goldani NA Fonseca VC Prates D Zaffan C Voegeli, et al. Transplant Proc 2001 33 1-2 1194 1195 10.1016/S0041-1345(00) 02382-4 11267254